Online CME/Enduring Materials

Acute Myeloid Leukemia: What’s New on the Horizon – T1010-E

1.00 AMA PRA Category 1 Credits ^TM from April 22, 2020 thru April 22, 2021

While guidelines for AML management are widely available, the treatment paradigm for AML is undergoing a rapid change in the settings of frontline treatment of younger patients with AML, older patients with AML not fit for intensive chemotherapy, and relapsed/refractory AML. Ensuring adjustments of these changes will avoid care limitations in terms of the clinical support team’s ability to utilize recent advances and adapt to changes in practice. Clinicians may not be adequately prepared to effectively and safely employ new therapies or discuss promising investigational agents with their patients. Moreover, clinicians may not be adequately knowledgeable regarding emerging clinically relevant biomarkers associated with both approved and investigational therapy choices for their patients with AML.

AML Pathfinder – T1007-E

1.00 AMA PRA Category 1 Credit^TM from July 10, 2020 thru July 10, 2021

This integrated portal enhances learner access to tailored education. Built on a powerful web platform, Healio provides physicians and other health care professionals with personalized content based on their needs and areas of interest. The Healio Education Lab is a one stop resource for specialty specific education and quality content from the most trusted website dedicated to physician news, information and education. 

Clinical Advances in the Management of RCC: Role of Immunotherapies in Treatment - Expert Advantage Clinical Advances in the Landscape of Renal Cell Carcinoma – T1009-E2

1.25 AMA PRA Category 1 Credits TM from July 10, 2020 to July 10, 2021

Utilization of appropriate combination therapies alongside immunotherapy agents for treatment of RCC Practical management strategies for immune-related adverse events arising from use of immunotherapy agents for treatment of RCC

Clinical Advances in the Management of RCC: Role of Immunotherapies in Treatment - Treatment Review for Intermediate Risk RCC: Clinical Cases – T1009-E3

.50 AMA PRA Category 1 Credits TM from July 10, 2020 to July 10, 2021

Utilization of appropriate combination therapies alongside immunotherapy agents for treatment of RCC Practical management strategies for immune-related adverse events arising from use of immunotherapy agents for treatment of RCC

Clinical Advances in the Management of RCC: Role of Immunotherapies in Treatment - Advanced RCC Clinical Case Review – T1009-E4

.50 AMA PRA Category 1 Credits ^TM from July 10, 2020 to July 10, 2021

Utilization of appropriate combination therapies alongside immunotherapy agents for treatment of RCC Practical management strategies for immune-related adverse events arising from use of immunotherapy agents for treatment of RCC

Targeting B-Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context - T1006-E

2.00 AMA PRA Category 1 Credit^TM from December 4, 2019 thru December 4, 2020

The curriculum is designed for hematologist/oncologists, nurse practitioners/physician assistants, pharmacists, and other health care providers and its collectively titled Targeting B-cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma: New Findings in Clinical Context. The overarching goal of the education is to improve awareness, knowledge, and eventual competence in the use of novel therapies that target BCMA in the treatment of relapsed/refractory multiple myeloma.

Optimizing Shared Decision Making in Lung Cancer (Today's Clinical Reality) E117619-1

.50 AMA PRA Category 1 Credits^TM from January 2, 2020 thru January 2, 2021

This activity will assess shared decision making between physician and patients. Patient and physician interviews/questionnaires will be utilized to measure the concordance between oncologist communication and treatment intentions and lunch cancer patient comprehension and treatment intentions based on National Quality Partners PlaybookTM guidance and recommendations.

Optimizing Shared Decision Marking in Lung Cancer (Strategies for Enhancing your Practice) E117619-2

.50 AMA PRA Category 1 Credits^TM .50 AMA PRA Category 1 CreditsTM in the area of medical ethics and/or professional responsibility. from January 2, 2020 thru January 2, 2021

This activity will assess shared decision making between physician and patients. Patient and physician interviews/questionnaires will be utilized to measure the concordance between oncologist communication and treatment intentions and lunch cancer patient comprehension and treatment intentions based on National Quality Partners PlaybookTM guidance and recommendations.   

Optimimizing Shared Decision Marking in Lung Cancer - E117619

No CME Credits

Sepsis and Oncology Training Module - T1013-E

1.0 AMA PRA Category 1 Credits^TM from June 11, 2020 to June 11, 2021

This program will explore the unique complexities of sepsis in the cancer patient and will discuss sepsis screening, identification and treatment in this population. The goal of the activity is to ensure that clinicians caring for cancer patients understand the heightened susceptibility of cancer patients to sepsis and the resulting need for consistent screening.

Provider Tobacco and Nicotine Counseling for Adults and Adolescents - MEMV 1160

2.25 AMA PRA Category 1 Credits ^TM from June 12, 2017 thru June 12, 2021

This program is intended to educate physicians about the need to provide tobacco/nicotine counseling. It will cover current and future pharmacological options for tobacco/nicotine cessation, as well as behavioral treatments for nicotine dependence. The program will also illustrate practical skills for counseling adolescent patients about tobacco /nicotine products and providing age-appropriate prevention/cessation resources.